This article is more than 5 years old. Information may no longer be current.

Alcon reports 2005 global sales of $4.37 billion

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUNENBERG, Switzerland — Alcon reported total sales for 2005 of $4.37 billion, up 11.6% from $3.91 billion in 2004, the company announced in a press release. Surgical product sales led the company’s growth, posting $2.01 billion in sales for the year, with pharmaceuticals posting $1.77 billion and the consumer eye group reporting $583.9 million, the company said.

Sales were evenly split between the United States and the rest of the world, with U.S. sales of $2.19 billion and international sales of $2.17 billion.

During the fourth quarter, Alcon noted sales of glaucoma products increased 19.7% overall, led by a 37.8% rise in sales of Travatan (travoprost). Sales of the company’s infection/inflammation products rose almost 14% in the quarter, led by fluoroquinolone Vigamox (moxifloxacin). Alcon said Vigamox is the leading ocular anti-infective in the United States, with a 45.1% market share. Four months after its launch, nonsteroidal anti-inflammatory drug Nevanac (nepafenac) has a 19.4% market share in the United States, Alcon said. Ocular allergy medicines, including Patanol (olopatadine), increased sales by 18.3%.

Surgical sales rose 10.7% to $523.5 million in the fourth quarter, Alcon said. IOL sales increased 18.3%, led by the AcrySof ReSTOR and AcrySof Natural IQ IOLs. Refractive revenue declined by 11%, while cataract and vitrectomy system sales increased 7.9%, Alcon said in the release.